Fractyl Health, Inc. Common Stock Cash Flow Conversion Efficiency
Fractyl Health, Inc. Common Stock cash flow conversion efficiency. Based on the latest financial reports, Fractyl Health, Inc. Common Stock (GUTS) has a cash flow conversion efficiency ratio of 9.550x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.90 Million) by net assets ($-1.67 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Fractyl Health, Inc. Common Stock (2019–2025)
Cash flow conversion efficiency of Fractyl Health, Inc. Common Stock from 2019 to 2025. This chart illustrates how Fractyl Health, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Fractyl Health, Inc. Common Stock stock price for real-time trading data and today's change.
Fractyl Health, Inc. Common Stock Cash Flow Conversion Ratio Explained
Fractyl Health, Inc. Common Stock cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Fractyl Health, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fractyl Health, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see GUTS market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Luda Technology Group Limited
NYSE MKT:LUD
|
0.262x |
|
Grupo Ortiz Properties Socimi
MC:YGOP
|
0.009x |
|
Carbios
PA:ALCRB
|
-0.090x |
|
DAM CAPITAL ADVISORS LTD
NSE:DAMCAPITAL
|
0.011x |
|
The Joint Corp
NASDAQ:JYNT
|
0.138x |
|
Daesung Ind
KO:128820
|
0.002x |
|
Voyager Therapeutics Inc
NASDAQ:VYGR
|
-0.141x |
|
Libstar Holdings Ltd
JSE:LBR
|
0.087x |
Annual Cash Flow Conversion Efficiency for Fractyl Health, Inc. Common Stock (2019–2025)
The table below shows the annual cash flow conversion efficiency of Fractyl Health, Inc. Common Stock from 2019 to 2025. Review financial flexibility index of Fractyl Health, Inc. Common Stock to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $9.46 Million | $-90.33 Million | -9.550x | -314.31% |
| 2024-09-30 | $28.42 Million | $-65.52 Million | -2.305x | -1849.78% |
| 2023-09-30 | $-325.06 Million | $-42.82 Million | 0.132x | -28.12% |
| 2022-09-30 | $-252.32 Million | $-46.24 Million | 0.183x | +14.65% |
| 2021-09-30 | $-209.32 Million | $-33.46 Million | 0.160x | +107.69% |
| 2020-09-30 | $14.95 Million | $-31.07 Million | -2.078x | -1179.23% |
| 2019-09-30 | $-144.00 Million | $-27.73 Million | 0.193x | -- |
About Fractyl Health, Inc. Common Stock
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a nove… Read more